Endurance Bio (endurance-bio.com): no confident changes recorded yet; website history since November 2026. Homepage last checked 13 November 2026.
First recorded website
Observed 13 November 2026
Our earliest capture with readable facts. This is our first observation, not when the company introduced these things. These website claims are not independently verified.
Endurance Bio develops first-in-class oral small molecules, T-168 and T-621, that activate PGC-1α and TFEB to restore mitochondrial and lysosomal function in neurodegeneration.
Homepage
Displayed as customers on the website
Remiges Ventures · Florida Opportunity Fund · DeepWork Capital · Neuro-SysMed · Cure Parkinson's · Norges Parkinsonforbund · Stanford University · UF Innovate · Gator CoLab
All facts above belong to this capture. Unlisted fields mean we have no readable observation, not that they were absent.
Recorded changes
Newest observations first. Each interval bounds when the website changed; it is not an exact event date.
No changes recorded yet. Missing observations do not mean the company has not changed.
How it describes itself
Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.
Seen November 2026 · 1 capture · latest observed messagingReprogramming cells. Repairing neurons. Restoring lives.
Endurance Bio develops first-in-class oral small molecules, T-168 and T-621, that activate PGC-1α and TFEB to restore mitochondrial and lysosomal function in neurodegeneration.